SPRAVATO
PeakNDANASALSPRAYPriority Review
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPRAVATO is a nasal spray small molecule approved by the FDA in March 2019 for psychiatric indications. The product is administered via intranasal route and represents an innovative delivery mechanism for central nervous system disorders. Mechanism of action and specific indications are not publicly detailed in available data.
$80MPart D
Peak13.3 years to LOESPRAVATO is in peak commercial phase with $80M annual Part D spending, indicating a mature, stable revenue stream supporting established brand and commercial infrastructure teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Reward Emotion Learning and Ketamine Study
Started Aug 2021
70 enrolled
DepressionMajor Depressive DisorderTreatment Resistant Depression
Why This Matters for Your Career
Worked on SPRAVATO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.